Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BCA101 · 1 trial · 11 indications
Incidence and severity of AEs and SAEs
Incidence and severity of AEs and SAEs
Incidence of DLTs during the first cycle of treatment with BCA101 monotherapy or the combination of BCA101 and pembrolizumab.
| Arm | Type | Description |
|---|---|---|
| BCA101 Monotherapy | EXPERIMENTAL | Route: IV Infusion Frequency: QW Current Dose: 1500mg |
| BCA101 + pembrolizumab | EXPERIMENTAL | Route: IV Infusion Frequency: Q3W Dose: 200mg |
| Name | Type | Description |
|---|---|---|
| BCA101 | DRUG | EGFR/TGFβ fusion monoclonal antibody |
| Pembrolizumab | DRUG | anti-PD-1 |
Inclusion Criteria: * Patient must have measurable disease amendable to biopsy and be willing to undergo both a pre-treatment and on-treatment biopsy, as well as provide archival tumor if available from the primary tumor (a paraffin embedded tumor tissue block sufficient to obtain at least 10 secti...
BCA101 is an investigational small molecule being studied for the treatment of Head and Neck Squamous Cell Carcinoma. It is currently in Phase 1 clinical development, and its safety and tolerability are being evaluated in patients with EGFR-driven advanced solid tumors, including this indication.
BCA101 targets EGFR, a protein involved in cell growth and survival that is often overactive in certain cancers. By targeting EGFR, BCA101 is being studied as a potential treatment for EGFR-driven advanced solid tumors, including Head and Neck Squamous Cell Carcinoma.
BCA101 is being developed by Bicara Therapeutics Inc., a biopharmaceutical company. The company is conducting clinical trials to evaluate the safety and tolerability of BCA101 in patients with EGFR-driven advanced solid tumors.
BCA101 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to assess its safety and tolerability in patients.
BCA101 is being studied in a Phase 1 clinical trial with the identifier NCT04429542. This trial is evaluating the safety and tolerability of BCA101 as a monotherapy and in combination therapy in patients with EGFR-driven advanced solid tumors, including Head and Neck Squamous Cell Carcinoma.
BCA101 is the drug name used in clinical development by Bicara Therapeutics Inc. No alternative names for BCA101 have been reported in the clinical trial information, so it is not known to be the same as any other drug.